Amgen (AMGN) Submits Evolocumab BLA to FDA as Hgh Cholesterol Treatment
Tweet Send to a Friend
Amgen (Nasdaq: AMGN) announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE